Scleroderma lung study reveals how pneumonia progresses over two years
NCT ID NCT03271333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 56 adults with systemic sclerosis (scleroderma) who also had a serious lung complication called diffuse infiltrating pneumonia. Researchers measured lung function at 12 and 24 months to see how it changed and to identify factors that might predict faster decline. The goal was to better understand the disease's course, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AH-HP, Hôpital Saint Antoine
Paris, 75571, France
-
Hôpital Claude Huriez, CHU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Blood particles may reveal hidden clues to scleroderma complications
- Could a simple injection dissolve painful calcium lumps in rare diseases?
- Finger injections aim to loosen stiff hands in scleroderma
- Continued anifrolumab treatment studied for lupus and related diseases
- Blood thinner may stop autoimmune disease before it starts